Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance

Gynecol Oncol. 2020 Dec;159(3):604-606. doi: 10.1016/j.ygyno.2020.09.017. Epub 2020 Sep 28.
No abstract available

Keywords: Maintenance therapy; Ovarian neoplasms; Poly(ADP-ribose) polymerase inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Chemotherapy, Adjuvant / methods
  • Clinical Decision-Making
  • Clinical Trials as Topic
  • Cytoreduction Surgical Procedures
  • Evidence-Based Medicine / methods
  • Female
  • Humans
  • Maintenance Chemotherapy / methods
  • Neoadjuvant Therapy / methods*
  • Neoplasm Staging
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / therapy*
  • Ovariectomy
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Practice Guidelines as Topic
  • Precision Medicine / methods
  • Progression-Free Survival

Substances

  • Angiogenesis Inhibitors
  • Biomarkers, Tumor
  • Poly(ADP-ribose) Polymerase Inhibitors